674
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.
 Weekly AUC2 carboplatin: Treatment; with or without oral phenoxodiol: Treatment; Weekly: Treatment.Freq; AUC2 carboplatin: Treatment.Drug; phenoxodiol: Treatment.Drug; platinum-resistant ovarian cancer: Treatment.Disorder; oral: Treatment.Route; phenoxodiol: Combination.Drug; AUC2 carboplatin: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 Weekly AUC2 carboplatin: Treatment; with or without oral phenoxodiol: Treatment; Weekly: Treatment.Freq; AUC2 carboplatin: Treatment.Drug; phenoxodiol: Treatment.Drug; platinum-resistant ovarian cancer: Treatment.Disorder; oral: Treatment.Route; phenoxodiol: Combination.Drug; AUC2 carboplatin: Combination.Drug